KRAS and BRAF mutation detection comparison across the different platforms.(A) Comparison of qBiomarker, AmpliSeq and ddPCR for the detection of clinically relevant KRAS and BRAF mutations in a panel of 51 PDX tumours. Red and blue dots indicate KRAS or BRAF mutations, respectively. Empty squares represent cases with no identified mutations. (B) Venn diagram summarising the number of mutations (KRAS and BRAF combined) detected by one of the methods alone (qBiomarker, AmpliSeq and ddPCR) and concomitantly. (C) Diagram representing KRAS (red dots) and BRAF (blue dots) mutations detected by qBiomarker, AmpliSeq, ddPCR and WES in 31 PDX models. Empty squares represent cases with no identified mutations.